Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Hellmann

MA19.01 Efficacy and Genomic Correlates of Response to Anti-Pd1/Pd-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes

Journal of Thoracic Oncology

English

MA19.09 Concurrent Mutations in STK11 and KEAP1 Is Associated With Resistance to PD-(L)1 Blockade in Patients With NSCLC Despite High TMB

Journal of Thoracic Oncology

English

MA04.05 Outcomes in NSCLC Patients Treated With First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

Journal of Thoracic Oncology

English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology

English

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

Journal of Thoracic Oncology

English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology

English

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers With Concurrent TP53 and RB1 Mutations

Journal of Thoracic Oncology

English

P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Hellmann

MA19.01 Efficacy and Genomic Correlates of Response to Anti-Pd1/Pd-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes

MA19.09 Concurrent Mutations in STK11 and KEAP1 Is Associated With Resistance to PD-(L)1 Blockade in Patients With NSCLC Despite High TMB

MA04.05 Outcomes in NSCLC Patients Treated With First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers With Concurrent TP53 and RB1 Mutations

P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001